Risk factors for postoperative venous thromboembolism in patients with lung cancer: a systematic review and meta-analysis

Objective: Venous thromboembolism (VTE) is a serious complication following lung cancer surgery, which not only complicates treatment but may also delay cancer-specific therapies and even threaten patient survival. Currently, the risk factors for postoperative VTE in lung cancer patients remain unclear. Therefore, we conducted a meta-analysis to identify risk factors associated with VTE in these patients after surgery.

Methods: We systematically searched PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Database, Chinese Biomedical Literature Database (CBM), and VIP Database for studies investigating risk factors for VTE after lung cancer surgery. The search covered the period from database inception to February 2025. Two reviewers independently screened the literature based on the inclusion and exclusion criteria, extracted data, and assessed the risk of bias in the included studies. Meta-analysis was performed using RevMan 5.4 software.

Results: A total of 21 studies involving 41,780 participants were included. The meta-analysis identified the following significant risk factors for VTE after lung cancer surgery: age ≥ 65 years old, hyperlipidemia, tumor staging III–IV, thoracotomy, operation time ≥ 2 h, intraoperative blood loss ≥ 200 mL, abnormal D-dimer levels, and preoperative chemotherapy. In contrast, no statistically significant associations were found between VTE occurrence and sex, age ≥ 60 years, smoking history, drinking history, body mass index ≥ 25 kg/m², hypertension, coronary heart disease, diabetes, pathological type, operation time ≥ 3 h, tumor location, or type of lung resection.

Conclusion: This meta-analysis confirmed that age ≥ 65 years, hyperlipidemia, advanced tumor stage (III–IV), thoracotomy, prolonged operation time (≥ 2 h), significant intraoperative blood loss (≥ 200 mL), abnormal D-dimer, and preoperative chemotherapy were risk factors for VTE in lung cancer patients after surgery. Targeted preventive measures based on these factors may help improve clinical outcomes in this patient population.

1 Introduction

Lung cancer remains one of the most prevalent malignancies worldwide, with its incidence and mortality rates consistently ranking first among all cancers (1–5). For eligible patients, comprehensive treatment centered around surgery remains the primary clinical approach, as it effectively removes lesion tissues and improves survival outcomes (6, 7). However, surgical trauma in lung cancer patients can lead to coagulation dysfunction, resulting in a hypercoagulable state and altered hemorheology. Postoperative pain further impedes early mobilization (8, 9), collectively contributing to a high susceptibility to venous thromboembolism (VTE) after surgery (10). Studies have reported that the incidence of postoperative VTE in lung cancer patients ranges from approximately 7.3% to 13.9% (11). As a serious complication following lung cancer surgery, VTE not only complicates clinical management but may also delay cancer-specific treatment and even threaten patient survival (12). Therefore, identifying risk factors for VTE in these patients is crucial for improving prognosis. Although multiple studies have investigated these risk factors, their findings remain inconsistent (13–33). This study aims to evaluate the risk factors for VTE after lung cancer surgery through a meta-analysis, thereby providing evidence-based support for postoperative VTE prevention.

2 Methods

The study was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (34).

2.1 Literature search

A systematic literature search was performed across the following electronic databases: PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Database, the China Biomedical Literature Database (CBM), and VIP Database. The search period spanned from the inception of each database to February 2025 to identify all relevant studies investigating risk factors for VTE following lung cancer surgery. The search strategy combined Medical Subject Headings (MeSH) terms with free words, including but not limited to “lung cancer,” “venous thromboembolism,” “deep vein thrombosis,” “pulmonary embolism,” and “risk factor.” The specific search strategy used for PubMed is provided as an example in Supplementary Table S1.

2.2 Inclusion and exclusion criteria

The study eligibility criteria were defined as follows:

Inclusion criteria:

1. Participants: Patients aged 18 years or older who were pathologically diagnosed with lung cancer and underwent surgical resection;

2. Exposure: Investigation of risk factors for postoperative VTE;

3. Outcome: A clear diagnosis of VTE confirmed by imaging examinations;

4. Study design: Cohort or case–control studies.

Exclusion criteria:

1. Duplicate publication;

2. Studies published as case reports, conference abstracts, animal studies, reviews, etc.;

3. Publications with insufficient data for extraction;

4. Studies with a Newcastle–Ottawa Scale (NOS) score below 5 points.

2.3 Data extraction

Two investigators independently screened the retrieved literature, extracted data, and cross-checked their findings. Any disagreements were resolved through discussion until a consensus was reached. The extracted information included the first author, publication year, study design, sample size, VTE incidence, exposure factors examined, and reported outcomes.

2.4 Risk of bias assessment

The methodological quality and risk of bias of the included studies were assessed independently by two reviewers using the NOS. The NOS evaluates studies based on three domains: selection of study groups, comparability of groups, and ascertainment of either exposure or outcome. The total score ranges from 0 to 9 points. Studies were categorized as low (0–4 points), moderate (5–6 points), or high quality (7–9 points). Consistent with the exclusion criteria, only studies with a NOS score of 5 or higher were included in the final meta-analysis.

2.5 Statistical analysis

All meta-analyses were performed using RevMan software (version 5.4). For consistency, all outcome data were converted into odds ratios (ORs) with their corresponding 95% confidence intervals (CIs). Pooled ORs and 95% CIs were calculated for each risk factor. Heterogeneity across included studies was assessed using chi-square tests and quantified by the I² statistic. A fixed-effects model was used when no significant heterogeneity was present (p ≥ 0.10 and I² ≤ 50%); otherwise, a random-effects model was applied. Sensitivity analyses were conducted by alternating between the fixed- and random-effects models to evaluate the robustness of the pooled results. Publication bias was assessed using Egger’s test or funnel plots for risk factors that were reported in 10 or more studies.

3 Results

3.1 Literature retrieval results

The initial systematic search identified 7,597 potentially relevant records. Following a rigorous screening process of titles, abstracts, and full texts against the predefined inclusion and exclusion criteria, 21 studies (13–33) were ultimately included for meta-analysis (Figure 1). The included studies, conducted in the United States, China, and Canada and published between 2012 and 2024, comprised both case–control and cohort designs. Sample sizes ranged from 84 to 14,308 participants. The methodological quality assessed by the NOS was high, with scores ranging from 7 to 9. The VTE incidence rate across studies was 3.63%. The baseline characteristics of the included studies are summarized in Table 1.

Figure 1

Figure 1. Flowchart of literature selection.

Table 1

Table 1. Characteristics of the included studies.

3.2 Meta-analysis results

3.2.1 Patient factors

3.2.1.1 Sex

Twenty studies were included in the analysis. The meta-analysis indicated that sex was not significantly associated with the risk of VTE following lung cancer surgery (OR = 1.09, 95% CI (0.93, 1.29), p = 0.300; Figure 2).

Figure 2

Figure 2. Meta-analysis of the association between sex and postoperative venous thromboembolism in patients with lung cancer.

3.2.1.2 Age

A pooled analysis of six studies was performed to assess the influence of age. Based on four studies utilizing a threshold of 60 years, no significant association was found between age ≥ 60 years and postoperative VTE risk [OR = 1.74, 95% CI (0.76, 3.95), p = 0.190] (Figure 3). However, analysis of two studies that defined older age as ≥ 65 years identified it as a significant risk factor for VTE [OR = 1.95, 95% CI (1.45, 2.61), p < 0.00001] (Figure 4).

Figure 3

Figure 3. Meta-analysis of the association between age ≥ 60 years old and postoperative venous thromboembolism in patients with lung cancer.

Figure 4

Figure 4. Meta-analysis of the association between age ≥ 65 years old and postoperative venous thromboembolism in patients with lung cancer.

3.2.1.3 History of smoking

Thirteen studies provided data on smoking history. The meta-analysis revealed no statistically significant association between a history of smoking and the development of VTE after surgery [OR = 1.13, 95% CI (0.86, 1.49), p = 0.390] (Figure 5).

Figure 5

Figure 5. Meta-analysis of the association between smoking history and postoperative venous thromboembolism in patients with lung cancer.

3.2.1.4 Drinking history

Data from eight studies were analyzed for drinking history. The results showed no significant association between a history of drinking and postoperative VTE risk [OR = 1.27, 95% CI (0.93, 1.75), p = 0.140] (Figure 6).

Figure 6

Figure 6. Meta-analysis of the association between drinking history and postoperative venous thromboembolism in patients with lung cancer.

3.2.1.5 Body mass index (BMI)

Seven studies were included to evaluate BMI. The meta-analysis demonstrated that a BMI ≥ 25 kg/m² was not significantly associated with an increased risk of VTE [OR = 1.03, 95% CI (0.84, 1.27), p = 0.780] (Figure 7).

Figure 7

Figure 7. Meta-analysis of the association between body mass index ≥ 25 kg/m² and postoperative venous thromboembolism in patients with lung cancer.

3.2.2 Disease condition

3.2.2.1 Hypertension

Fourteen studies were included. The meta-analysis found no statistically significant association between hypertension and the risk of VTE after lung cancer surgery [OR = 1.30,95% CI (1.00,1.68), p = 0.050] (Figure 8).

Figure 8

Figure 8. Meta-analysis of the association between hypertension and postoperative venous thromboembolism in patients with lung cancer.

3.2.2.2 Hyperlipidemia

Pooled results from three studies indicated that hyperlipidemia was a significant risk factor for VTE [OR = 2.21, 95% CI (1.22, 4.02), p = 0.009] (Figure 9).

Figure 9

Figure 9. Meta-analysis of the association between hyperlipidemia and postoperative venous thromboembolism in patients with lung cancer.

3.2.2.3 Tumor staging

Analysis of 15 studies demonstrated that advanced tumor stage (III–IV) was significantly associated with an increased risk of VTE [OR = 1.76, 95%CI (1.29, 2.41), p = 0.0004] (Figure 10).

Figure 10

Figure 10. Meta-analysis of the association between tumor staging and postoperative venous thromboembolism in patients with lung cancer.

3.2.2.4 Coronary heart disease

Data from eight studies were analyzed. The meta-analysis showed that coronary heart disease was not significantly associated with VTE risk [OR = 1.16, 95%CI (0.83, 1.62), p = 0.390] (Figure 11).

Figure 11

Figure 11. Meta-analysis of the association between coronary heart disease and postoperative venous thromboembolism in patients with lung cancer.

3.2.2.5 Diabetes

Fourteen studies provided data on diabetes. No significant association was found between diabetes and postoperative VTE [OR = 1.32, 95%CI (0.96, 1.81), p = 0.090] (Figure 12).

Figure 12

Figure 12. Meta-analysis of the association between diabetes and postoperative venous thromboembolism in patients with lung cancer.

3.2.2.6 Pathological type

Based on 14 studies, the pathological type (adenocarcinoma versus other types) was not significantly associated with VTE risk [OR = 0.87, 95%CI (0.74, 1.02), p = 0.080] (Figure 13).

Figure 13

Figure 13. Meta-analysis of the association between pathological type and postoperative venous thromboembolism in patients with lung cancer.

3.2.3 Surgery-related factors

3.2.3.1 Type of surgery

Ten studies compared surgical approaches. The meta-analysis identified thoracotomy as a significant risk factor for VTE [OR = 1.76, 95% CI (1.43, 2.16), p < 0.00001] (Figure 14).

Figure 14

Figure 14. Meta-analysis of the association between the surgical approach and postoperative venous thromboembolism in patients with lung cancer.

3.2.3.2 Operation time

Five studies examined the effect of operation time. Analysis of three studies using a 3-h threshold showed no statistically significant association with VTE risk [OR = 1.59, 95%CI (1.01, 2.50), p = 0.050] (Figure 15). However, based on two studies using a 2-h threshold, an operation time ≥ 2 h was a significant risk factor [OR = 2.86, 95%CI (1.71, 4.77), p < 0.0001] (Figure 16).

Figure 15

Figure 15. Meta-analysis of the association between operation time ≥ 3 h and postoperative venous thromboembolism in patients with lung cancer.

Figure 16

Figure 16. Meta-analysis of the association between operation time ≥ 2 h and postoperative venous thromboembolism in patients with lung cancer.

3.2.3.3 Intraoperative blood loss

Two studies reported intraoperative blood loss. The meta-analysis indicated that blood loss ≥ 200 mL was a significant risk factor for VTE.

[OR = 1.13, 95%CI (1.02, 1.25), p = 0.020] (Figure 17).

Figure 17

Figure 17. Meta-analysis of the association between intraoperative bleeding and postoperative venous thromboembolism in patients with lung cancer.

3.2.3.4 Tumor site

Data from five studies showed that tumor location (left versus right lung) was not significantly associated with VTE risk [OR = 0.95, 95%CI (0.68, 1.33), p = 0.770] (Figure 18).

Figure 18

Figure 18. Meta-analysis of the association between tumor site and postoperative venous thromboembolism in patients with lung cancer.

3.2.3.5 Type of lung resection

Six studies were included. The meta-analysis found that the type of lung resection (lobectomy versus other resections) was not significantly associated with VTE risk [OR = 0.89, 95%CI (0.47, 1.69), p = 0.730] (Figure 19).

Figure 19

Figure 19. Meta-analysis of the association between type of lung resection and postoperative venous thromboembolism in patients with lung cancer.

3.2.4 Other factors

3.2.4.1 Preoperative chemotherapy

Analysis of five studies showed that preoperative chemotherapy was a significant risk factor for VTE [OR = 3.40, 95%CI (1.92, 6.02), p < 0.0001] (Figure 20).

Figure 20

Figure 20. Meta-analysis of the association between preoperative chemotherapy and postoperative venous thromboembolism in patients with lung cancer.

3.2.4.2 Abnormal D-dimer

Based on four studies, an abnormal D-dimer level was identified as a significant risk factor for VTE [OR = 2.89, 95%CI (1.50, 5.60), p = 0.002] (Figure 21).

Figure 21

Figure 21. Meta-analysis of the association between D-dimer abnormality and postoperative venous thromboembolism in patients with lung cancer.

3.2.5 Publication bias

Funnel plots were generated for factors with sufficient included studies, such as sex, pathological type, tumor stage, and hypertension. The scatter points in these funnel plots showed approximate symmetry, suggesting a low likelihood of significant publication bias (Figure 22).

Figure 22

Figure 22. Funnel plot: (A) Sex; (B) pathological type; (C) tumor stage; and (D) hypertension.

3.2.6 Sensitivity analysis

Sensitivity analysis, performed by alternating between fixed-effect and random-effects models, demonstrated that the direction and significance of the pooled results for all risk factors remained consistent. This indicates that the findings are robust and not overly dependent on the choice of statistical model (Table 2).

Table 2

Table 2. Each outcome changed the model sensitivity analysis results.

4 Discussion

This meta-analysis, encompassing 21 studies with a total of 41,780 participants, evaluated 18 potential risk factors for VTE following lung cancer surgery. The results identified the following significant risk factors: age ≥ 65 years, hyperlipidemia, tumor stage III–IV, thoracotomy, operation time ≥ 2 h, intraoperative blood loss ≥ 200 mL, preoperative chemotherapy, and abnormal D-dimer levels.

Previous studies have consistently recognized advanced age as a risk factor for postoperative VTE in lung cancer patients (13, 16, 25, 31). However, the specific age threshold for risk stratification remains controversial. Our analysis demonstrated that patients aged 65 years or older had a significantly higher risk of VTE. This may be explained by age-related physiological decline, including diminished functional reserve, reduced muscle tone, endothelial dysfunction, and impaired venous compliance, all of which contribute to an elevated thromboembolic risk in the elderly surgical population (35). While some studies (13) have suggested smoking as a risk factor due to its role in vascular endothelial injury, platelet activation, increased blood viscosity, and slowed blood flow, thereby accelerating thrombosis (36), our meta-analysis did not find a statistically significant association between smoking history and VTE. We believe that the studies included might have only regarded smoking history as a binary variable of “present/absent,” failing to incorporate more precise indicators of exposure dose. Moreover, in the specific group of lung cancer patients, smoking itself is the primary causative factor (37). The baseline smoking rate among the study population was generally high, which might have weakened the effectiveness of the comparison between the groups. Similarly, although male sex has been linked to higher VTE incidence—possibly due to a higher prevalence of smoking and associated increases in blood viscosity with the long-term effect of nicotine in tobacco (21)—our results did not identify male sex as an independent risk factor.

Hyperlipidemia was confirmed as a significant risk factor for VTE after lung cancer surgery in this study. The underlying mechanism may involve vascular endothelial injury and enhanced platelet aggregation caused by high lipid levels. Elevated cholesterol and triglycerides can contribute to atherosclerotic plaque formation, narrowing the vascular lumen, impeding blood flow, and limiting postoperative mobility, thereby increasing thrombotic risk (38). Furthermore, advanced tumor stage (III–IV) was strongly associated with VTE, consistent with earlier reports such as that by Amer et al., who observed VTE incidences of 64.8% in stage III–IV patients compared to 34.2% in stage I–II patients (39). This may be attributed to cancer progression and metastasis exacerbating systemic hypercoagulability (20). Although some evidence suggests that lung adenocarcinoma carries a higher VTE risk compared to squamous cell carcinoma (40), our analysis did not find a statistically significant association between its pathological subtype and postoperative VTE.

Our study identified several surgery-related factors as significant contributors to VTE risk. Specifically, thoracotomy, an operation time ≥ 2 h, and intraoperative blood loss ≥ 200 mL were all independently associated with an increased incidence of VTE following lung cancer surgery. During lung cancer surgery, the clamping and manipulation of major blood vessels can cause trauma to local arteries and veins. Compared to video-assisted thoracic surgery, open thoracotomy inevitably leads to more extensive tissue damage, which elevates systemic stress levels and promotes the release of inflammatory factors. This inflammatory response can induce endothelial cell dysfunction, thereby activating the coagulation system and ultimately promoting thrombus formation (41). Consequently, lung cancer patients undergoing thoracotomy are at a higher risk of developing VTE. Prolonged operative time directly extends both anesthesia duration and immobilization period, which may cause vascular endothelial injury and alter hemodynamics, leading to reduced venous pressure and decreased blood flow velocity, thereby increasing the risk of thrombosis (42, 43). However, the findings of this study indicated that while an operative time of ≥2 h was a risk factor for VTE, a threshold of ≥3 h did not show statistical significance. This discrepancy may be attributed to the limited number of studies included. Increased intraoperative blood loss leads to hemoconcentration, and concomitant peripheral vasoconstriction slows blood flow, collectively promoting thrombosis (44). Additionally, prolonged bed rest after surgery can cause reduced and stagnant blood flow in the lower extremity veins, which may also elevate the risk of thrombosis (45).

Studies have shown that there is a statistically significant positive correlation between BMI and VTE (46). However, in oncology, there is a notable “obesity paradox” phenomenon (47). For lung cancer patients, obesity is associated with better postoperative prognosis and lower incidence. Patients with mild overweight may have a survival advantage when dealing with surgical stress due to better metabolic reserves and nutritional status (47, 48).

Preoperative chemotherapy was also identified as a significant risk factor in our study. Platinum-based agents, in particular, are known to enhance thrombin generation and reduce levels of natural anticoagulants such as proteins S and C. Many chemotherapeutic drugs can directly injure vascular endothelial cells, activate the coagulation system, and suppress fibrinolysis, collectively increasing thrombosis risk (49, 50). Finally, elevated D-dimer—a fibrin degradation product reflecting fibrinolytic activity—was confirmed as a risk factor in this study. It serves as an important biomarker in the diagnosis of thrombosis and pulmonary microvascular embolism (51), and our results support its value in predicting VTE after lung cancer surgery.

5 Limitations

This study has several limitations (1): Only Chinese and English publications were included, potentially overlooking relevant studies in other languages and introducing selection bias (2). Some risk factors (e.g., age ≥ 65 years old, operation time ≥ 2 h, operation time ≥ 3 h, hyperlipidemia, and intraoperative blood loss ≥200 mL) were analyzed based on a limited number of studies and small sample sizes. Due to the limited number of included studies, this may affect the stability of the combined effect values and statistical power. Therefore, the interpretation of the strength of association for these specific factors should be cautious (3). Variability in follow-up durations across the included studies may have affected the accuracy of postoperative VTE incidence estimates (4). Due to the limited availability of data, it was not feasible to evaluate all potential risk factors (5). Specific genetic mutations (e.g., ALK, EGFR, and KRAS) and related targeted therapies (such as EGFR-TKI inhibitors) may have distinct associations with thrombotic risk; however, due to insufficient reporting in the original studies, this aspect could not be incorporated into our analysis. Therefore, it is suggested that multi-center and large-sample epidemiological studies be carried out in the future to further clarify the related risk factors for VTE in patients after lung cancer surgery.

6 Conclusion

This meta-analysis identified the following significant risk factors for postoperative VTE in lung cancer patients: age ≥ 65 years, hyperlipidemia, advanced tumor stage (III–IV), thoracotomy, operation time ≥ 2 h, intraoperative blood loss ≥ 200 mL, abnormal D-dimer levels, and preoperative chemotherapy. Prior to scheduling surgery, clinicians should thoroughly evaluate whether patients exhibit these risk factors to mitigate the incidence of VTE. Future multi-center, large-sample epidemiological studies are recommended to further elucidate the risk factors associated with VTE in this patient population.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author/s.

Author contributions

JF: Writing – original draft, Writing – review & editing. YZ: Writing – review & editing, Writing – original draft. FZ: Writing – review & editing, Validation, Conceptualization, Methodology. RL: Validation, Writing – review & editing, Investigation, Conceptualization. LH: Funding acquisition, Conceptualization, Writing – review & editing, Supervision, Methodology. HZ: Funding acquisition, Writing – review & editing, Supervision, Conceptualization, Methodology, Project administration.

Funding

The author(s) declared that financial support was not received for this work and/or its publication.

Acknowledgments

The authors thank the authors of the included studies who shared the important data.

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that Generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2025.1699892/full#supplementary-material

References

1. Bray, F, Laversanne, M, Sung, H, Ferlay, J, Siegel, RL, Soerjomataram, I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2024) 74:229–63. doi: 10.3322/caac.21834,

PubMed Abstract | Crossref Full Text | Google Scholar

2. Siegel, RL, Miller, KD, Fuchs, HE, and Jemal, A. Cancer Statistics, 2021. CA Cancer J Clin. (2021) 71:7–33. doi: 10.3322/caac.21654,

PubMed Abstract | Crossref Full Text | Google Scholar

3. Wang, J, Yang, Y, Lu, S, Huang, J, Li, S, Chang, H, et al. Electroacupuncture combined with cisplatin induces an effective anti-tumor immune response by protecting chemotherapy-impaired bone marrow hematopoiesis in non–small cell lung cancer mice. Acupunct Herb Med. (2025) 5:229–45. doi: 10.1097/HM9.0000000000000158

Crossref Full Text | Google Scholar

4. Zhang, Y, You, P, Liu, R, Lu, Y, Li, J, Lei, Y, et al. Artificial intelligence in clinical trials of lung cancer: Current and future prospects. Intell Oncol. (2025) 1:34–51. doi: 10.1016/j.intonc.2024.11.003

Crossref Full Text | Google Scholar

5. Wu, S, Zhuang, A, Huang, G, Zhao, Z, Zhan, W, Lei, Y, et al. A narrative review of the prediction of immunotherapy efficacy for treating NSCLC: An artificial intelligence perspective. Intell Oncol. (2025) 1:193–203. doi: 10.1016/j.intonc.2025.05.001

Crossref Full Text | Google Scholar

6. Ma, X, Han, S, Nie, J, et al. Diagnosis and Treatment Characteristics of Lung Cancer Patients with Venous Thromboembolism. Cancer Res Prev Treat. (2020) 47:335–9. doi: 10.3971/j.issn.1000-8578.2020.19.1243

Crossref Full Text | Google Scholar

7. Li, Z, Li, F, Han, B, and Yu, L. Clinical effect observation of unfractionated heparin versus low molecular weight heparin sodium in preventing venous thromboembolism in lung cancer patients. J Clin Med Pract. (2020) 24:51–4. doi: 10.7619/jcmp.202008013

Crossref Full Text | Google Scholar

8. Yu, Y, Zong, L, Zhang, H, Sheyhidin, I, and Zhu, H. Value of maximum amplitude of thrombus in thromboelastogram in predicting occurrence of venous thrombosis in patients after lung cancer surgery. Chin J Clin Thorac Cardiovasc Surg. (2022) 29:899–903. doi: 10.7507/1007-4848.202012010

Crossref Full Text | Google Scholar

9. Adelborg, K, Larsen, JB, and Hvas, AM. Disseminated intravascular coagulation: epidemiology, biomarkers, and management. Br J Haematol. (2021) 192:803–18. doi: 10.1111/bjh.17172,

PubMed Abstract | Crossref Full Text | Google Scholar

10. Ay, C, and Ünal, UK. Epidemiology and risk factors for venous thromboembolism in lung cancer. Curr Opin Oncol. (2016) 28:145–9. doi: 10.1097/cco.0000000000000262,

PubMed Abstract | Crossref Full Text | Google Scholar

11. Li, H, and Jiang, G. Perioperative Venous Thromboembolism (VTE) Prophalaxis in Thoracic Cancer Patients: Chinese Experts Consensus. Chin J Lung Cancer. (2018) 21:739–52. doi: 10.3779/j.issn.1009-3419.2018.10.03,

PubMed Abstract | Crossref Full Text | Google Scholar

12. Du, C, Yu, Z, Liu, Z, and Lv, Y. Risk factors of venous thromboembolism in lung cancer patients. Clin J Med. (2020) 48:5–7. doi: 10.16680/j.1671-3826.2020.01.02

Crossref Full Text | Google Scholar

13. Wu, J, Cui, P, Xi, F, et al. Related influencing factors of VTE in postoperative patients with lung cancer. Pract J Cancer. (2023) 38:615–617+621. doi: 10.3969/j.issn.1001-5930.2023.04.024

Crossref Full Text | Google Scholar

14. Wang, H. Analysis of risk factors of venous thromboembolism in patients with lung cancer after surgery. Thesis (2021).

Google Scholar

15. Qin, D. Analysis of risk factors and thrombelastography value of postoperative venous thromboembolism in patients with lung cancer. Thesis. Jilin University (2022).

Google Scholar

16. Ke, J, Xie, Y, and Huang, L. Risk factors analysis of venous thromboembolism in patients underwent the lung cancer operation. Nurs Pract Res. (2021) 18:1908–11. doi: 10.3969/j.issn.1672-9676.2021.13.004

Crossref Full Text | Google Scholar

17. Jia, J, Zhang, Y, Liu, Y, Zhang, L, Yu, H, and Hu, B. Risk factor of lower extremity deep vein thrombosis during postoperative hospitalization in patients with lung cancer. J Vasc Endovasc Surg. (2023) 9:45–48+53. doi: 10.19418/j.cnki.issn2096-0646.2023.01.10

Crossref Full Text | Google Scholar

18. Cui, S, Li, H, Tian, B, Song, C, and Hu, B. Risk Factors Associated with Venous Thromboembolism after Lung Cancer Surgery: A Single-center Study. Zhongguo Fei Ai Za Zhi. (2018) 21:753–60. doi: 10.3779/j.issn.1009-3419.2018.10.04,

PubMed Abstract | Crossref Full Text | Google Scholar

19. Zhang, X, Luo, B, Han, F, and Liu, Q. Risk factors and prediction model construction for venous thromboembolism in patients after thoracoscopic surgery for lung cancer. China Med. (2022) 17:1477–81. doi: 10.3760/j.issn.1673-4777.2022.10.009

Crossref Full Text | Google Scholar

20. Awang, D, Deji, Q, Lv, G, and Wang, K. Risk factors for deep vein thrombosis of the lower extremities in elderly patients with lung cancer after surgery. Zhonghua Yi Xue Za Zhi. (2017) 37:3511–3. doi: 10.3969/j.issn.1005-9202.2017.14.059

Crossref Full Text | Google Scholar

21. Zhou, D, Ren, G, Shu, Y, and Hu, X. Analysis of the influence of deep venous thrombosis of lower limbs in elderly patients with lung cancer after operation. J Vasc Endovasc Surg. (2019) 5:342–5. doi: 10.19418/j.cnki.issn2096-0646.2019.04.016

Crossref Full Text | Google Scholar

22. Qiao, A, Ma, Y, Chen, W, et al. High-risk factors affecting lower limb deep venous thrombosis after thoracoscopic lung cancer resection. J Vasc Endovasc Surg. (2021) 7:52–55+70. doi: 10.19418/j.cnki.issn2096-0646.2021.01.10

Crossref Full Text | Google Scholar

23. Dong, HH, Cai, YS, Liang, XN, et al. Analysis of incidence and risk factors for postoperative venous thromboembolism in patients with stageI a non-small-cell lung cancer. Zhonghua Yi Xue Za Zhi. (2021) 101:3417–21. doi: 10.3760/cma.j.cn112137-20210418-00929

Crossref Full Text | Google Scholar

24. Akhtar-Danesh, GG, Akhtar-Danesh, N, and Shargall, Y. Venous Thromboembolism in Surgical Lung Cancer Patients: A Provincial Population-Based Study. Ann Thorac Surg. (2022) 114:890–7. doi: 10.1016/j.athoracsur.2021.10.018,

PubMed Abstract | Crossref Full Text | Google Scholar

25. Du, H, Zhao, H, Zhao, Q, and Chen, J. Analysis of the incidence of lower limb deep venous thrombosis and its related risk factors in the postoperative patients with lung cancer. Zhongguo Fei Ai Za Zhi. (2023) 26:386–91. doi: 10.3779/j.issn.1009-3419.2023.102.16,

PubMed Abstract | Crossref Full Text | Google Scholar

26. Yang, Y, Zhou, Z, Niu, XM, Li, ZM, Chen, ZW, Jian, H, et al. Clinical analysis of postoperative venous thromboembolism risk factors in lung cancer patients. J Surg Oncol. (2012) 106:736–41. doi: 10.1002/jso.23190,

PubMed Abstract | Crossref Full Text | Google Scholar

27. Dong, H, Liang, X, Gao, Y, Cai, Y, Li, X, Miao, J, et al. Postoperative venous thromboembolism after surgery for stage IA non-small-cell lung cancer: A single-center, prospective cohort study. Thorac Cancer. (2022) 13:1258–66. doi: 10.1111/1759-7714.14373,

PubMed Abstract | Crossref Full Text | Google Scholar

28. Qin, D, Cai, H, Liu, Q, Lu, T, Tang, Z, Shang, Y, et al. Nomogram model combined thrombelastography for venous thromboembolism risk in patients undergoing lung cancer surgery. Front Physiol. (2023) 14:1242132. doi: 10.3389/fphys.2023.1242132,

PubMed Abstract | Crossref Full Text | Google Scholar

29. Song, C, Shargall, Y, Li, H, Tian, B, Chen, S, Miao, J, et al. Prevalence of venous thromboembolism after lung surgery in China: a single-centre, prospective cohort study involving patients undergoing lung resections without perioperative venous thromboembolism prophylaxis†. Eur J Cardiothorac Surg. (2019) 55:455–60. doi: 10.1093/ejcts/ezy323,

PubMed Abstract | Crossref Full Text | Google Scholar

30. Ding, Y, Yao, L, Tan, T, Li, Q, Shi, H, Tian, Y, et al. Risk assessment for postoperative venous thromboembolism using the modified Caprini risk assessment model in lung cancer. J Thorac Dis. (2023) 15:3386–96. doi: 10.21037/jtd-23-776,

PubMed Abstract | Crossref Full Text | Google Scholar

31. Thomas, DC, Arnold, BN, Hoag, JR, Salazar, MC, Detterbeck, FC, Boffa, DJ, et al. Timing and Risk Factors Associated With Venous Thromboembolism After Lung Cancer Resection. Ann Thorac Surg. (2018) 105:1469–75. doi: 10.1016/j.athoracsur.2018.01.072,

PubMed Abstract | Crossref Full Text | Google Scholar

32. Li, YP, Shen, L, Huang, W, Hu, X-f, Xie, D, Yang, J, et al. Prevalence and risk factors of acute pulmonary embolism in patients with lung cancer surgery. Semin Thromb Hemost. (2018) 44:334–40. doi: 10.1055/s-0037-1612625,

PubMed Abstract | Crossref Full Text | Google Scholar

33. Hei, X, Zhang, B, Cui, M, and Wang, X. Risk factors for pulmonary embolism during postoperative hospitalization in patients with lung cancer. J Vasc Endovasc Surg. (2023) 9:300–3. doi: 10.19418/j.cnki.issn2096-0646.2023.03.09

Crossref Full Text | Google Scholar

34. Zhu, Z, Yuan, X, Zheng, Y, Dou, B, Liu, L, Loh, PY, et al. Effectiveness of acupuncture in managing aromatase inhibitor-related arthralgia in breast cancer: a systematic review and meta-analysis. Acupunct Herb Med. (2025) 5:352–65. doi: 10.1097/HM9.0000000000000172

Crossref Full Text | Google Scholar

35. Huang, J, Chen, X, and Pan, L. Clinical characteristics of venous thromboembolism in elderly critically ill patients. Label Immunoassays Clin Med. (2022) 29:1248–51. doi: 10.11748/bjmy.issn.1006-1703.2022.07.034

Crossref Full Text | Google Scholar

36. Wang, S, Wang, W, Pan, L, and Zhang, M. Changes of coagulation function in patients with lung cancer and its clinical significance. Chin J Clin Lab Sci. (2020) 27:1637–41. doi: 10.11748/bjmy.issn.1006-1703.2020.10.001

Crossref Full Text | Google Scholar

37. Malhotra, J, Malvezzi, M, Negri, E, La Vecchia, C, and Boffetta, P. Risk factors for lung cancer worldwide. Eur Respir J. (2016) 48:889–902. doi: 10.1183/13993003.00359-2016,

PubMed Abstract | Crossref Full Text | Google Scholar

38. Liu, X, and Xu, X. Diagnosis and treatment characteristics of lung cancer patients with venous thromboembolism. Guangdong Med J. (2013) 34:1295–7. doi: 10.13820/j.cnki.gdyx.2013.08.073

Crossref Full Text | Google Scholar

39. Amer, MH. Cancer-associated thrombosis: clinical presentation and survival. Cancer Manag Res. (2013) 5:165–78. doi: 10.2147/cmar.S47094,

PubMed Abstract | Crossref Full Text | Google Scholar

40. Walker, AJ, Baldwin, DR, Card, TR, Powell, HA, Hubbard, RB, and Grainge, MJ. Risk of venous thromboembolism in people with lung cancer: a cohort study using linked UK healthcare data. Br J Cancer. (2016) 115:115–21. doi: 10.1038/bjc.2016.143,

PubMed Abstract | Crossref Full Text | Google Scholar

41. Preston, RJS, O'Sullivan, JM, and O'Donnell, JS. Advances in understanding the molecular mechanisms of venous thrombosis. Br J Haematol. (2019) 186:13–23. doi: 10.1111/bjh.15869,

PubMed Abstract | Crossref Full Text | Google Scholar

42. Zhu, Q, Tang, T, and Liu, H. Risk factors and prevention of venous thromboembolism in patients undergoing surgery for lung cancer. Nurs Integr Tradit Chin West Med. (2019) 5:193–6. doi: 10.11997/nitcwm.201906060

Crossref Full Text | Google Scholar

43. Ye, H, Wang, Z, and Wang, Z. Effect of low molecular weight heparin in cancer patients with hypercoagulable states and survival analysis. Chin J Diffic Complicated Cases. (2016) 15:273–5. doi: 10.3969/j.issn.1671-6450.2016.03.014

Crossref Full Text | Google Scholar

44. Molena, D, Mungo, B, Stem, M, Feinberg, RL, and Lidor, AO. Prevalence, impact, and risk factors for hospital-acquired conditions after major surgical resection for cancer: a NSQIP analysis. J Gastrointest Surg. (2015) 19:142–151; discussion 151. doi: 10.1007/s11605-014-2642-x,

PubMed Abstract | Crossref Full Text | Google Scholar

45. Wang, D, Xiong, W, and Han, F. Research progress on the pathogenesis of venous thromboembolism caused by lung cancer. Chin J Respir Crit Care Med. (2023) 22:135–41. doi: 10.7507/1671-6205.202206054

Crossref Full Text | Google Scholar

46. Severinsen, MT, Kristensen, SR, Johnsen, SP, Dethlefsen, C, Tjønneland, A, and Overvad, K. Anthropometry, body fat, and venous thromboembolism: a Danish follow-up study. Circulation. (2009) 120:1850–7. doi: 10.1161/circulationaha.109.863241,

PubMed Abstract | Crossref Full Text | Google Scholar

47. Yao, S, Zeng, L, Wang, F, and Chen, K. Obesity Paradox in Lung Diseases: What Explains It? Obes Facts. (2023) 16:411–26. doi: 10.1159/000531792,

PubMed Abstract | Crossref Full Text | Google Scholar

48. Petrelli, F, Cortellini, A, Indini, A, Tomasello, G, Ghidini, M, Nigro, O, et al. Association of obesity with survival outcomes in patients with cancer: a systematic review and meta-analysis. JAMA Netw Open. (2021) 4:e213520. doi: 10.1001/jamanetworkopen.2021.3520,

PubMed Abstract | Crossref Full Text | Google Scholar

49. Matsumoto, Y, Horimasu, Y, Yamaguchi, K, Sakamoto, S, Masuda, T, Nakashima, T, et al. D-dimer can be a diagnostic marker for cisplatin-related aortic thrombosis: A case report. Medicine (Baltimore). (2021) 100:e24695. doi: 10.1097/md.0000000000024695,

PubMed Abstract | Crossref Full Text | Google Scholar

50. Mitani, A, Jo, T, Yasunaga, H, Sakamoto, Y, Hasegawa, W, Urushiyama, H, et al. Venous thromboembolic events in patients with lung cancer treated with cisplatin-based versus carboplatin/nedaplatin-based chemotherapy. Anti-Cancer Drugs. (2018) 29:560–4. doi: 10.1097/cad.0000000000000625,

PubMed Abstract | Crossref Full Text | Google Scholar

51. Prandoni, P, Vedovetto, V, Ciammaichella, M, Bucherini, E, Corradini, S, Enea, I, et al. Residual vein thrombosis and serial D-dimer for the long-term management of patients with deep venous thrombosis. Thromb Res. (2017) 154:35–41. doi: 10.1016/j.thromres.2017.04.002,

PubMed Abstract | Crossref Full Text | Google Scholar